Letter from the Editor

Dear Colleagues,

Thank you for reading this edition of Medicom’s Conference Report focused on HFA 2021. In the following pages you will see a broad summary of this rich and high-quality scientific meeting.

Several late-breaking trials were presented including data for Omecamtiv, Vericiguat, Dapagliflozin, and Iron. There are focused sections on COVID-19, cardiooncology, and quality of life. A special focused section covers several exciting analyses of SGLT2 inhibitors and their effects on biomarkers as well as observed effects in real-world datasets.

As always, we have strived to provide balanced, concise, and informative summaries of these analyses. Thank you again for your readership and we hope you find these materials engaging and informative.

Sincerely,

Marc Bonaca



 

Biography

Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.

Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.

Conflict of Interest Statement:

Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi

 



Posted on 20 August, 2021